Ultragenyx Pharmaceutical Inc (RARE)

53.67
1.00 2.00
NASDAQ : Health Care
Prev Close 52.63
Open 52.87
Day Low/High 51.99 / 54.75
52 Wk Low/High 46.52 / 135.43
Volume 205.96K
Avg Volume 310.20K
Exchange NASDAQ
Shares Outstanding 42.46M
Market Cap 2.20B
EPS -4.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Ultragenyx And Kyowa Hakko Kirin Announce Additional Burosumab Data In X-Linked Hypophosphatemia (XLH) And Tumor-Induced Osteomalacia (TIO) At ASBMR

Ultragenyx And Kyowa Hakko Kirin Announce Additional Burosumab Data In X-Linked Hypophosphatemia (XLH) And Tumor-Induced Osteomalacia (TIO) At ASBMR

Positive data in bone disease in pediatric XLH patients under 5 years old and in TIO patients

Ultragenyx Announces Top-Line Results From Phase 3 Study Of Ace-ER In GNE Myopathy

Ultragenyx Announces Top-Line Results From Phase 3 Study Of Ace-ER In GNE Myopathy

Study did not meet its primary endpoint

Ultragenyx Reports Second Quarter 2017 Financial Results And Corporate Update

Ultragenyx Reports Second Quarter 2017 Financial Results And Corporate Update

Burosumab US BLA submission planned for August 2017

Ultragenyx Provides Regulatory Update On Burosumab (KRN23)

BLA filing for Burosumab planned with current clinical data package in 2H 2017

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Apple Could Explode Higher to $200 a Share If This Chart Pattern Is Correct

Huge profits could be on the doorstep for these hot breakout setups.

Newman Ferrara LLP Announces Corporate Governance Investigation Of Ultragenyx Pharmaceutical Inc.

Newman Ferrara LLP announced today that the firm is conducting an investigation on behalf of shareholders of Ultragenyx Pharmaceutical Inc.

Ultragenyx Reports First Quarter 2017 Financial Results And Corporate Update

Additional Phase 3 data on burosumab shows increased healing of fractures in adult XLH

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Biotech Movers: Ultragenyx Jumps on Phase Three Burosumab Data

Ultragenyx, together with Kyowa Hakko Kirin and Kyowa Kirin International, on Tuesday unveiled 24-week data from a phase three study of burosumab in adults.

Notable Friday Option Activity: RARE, EVC, W

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ultragenyx Pharmaceutical Inc , where a total volume of 4,232 contracts has been traded thus far today, a contract volume which is representative of approximately 423,200 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 64% of RARE's average daily trading volume over the past month, of 661,320 shares.

Ultragenyx And Kyowa Kirin International Announce Positive Data From Pediatric Phase 2 Studies Of Burosumab (KRN23) In X-Linked Hypophosphatemia

Sustained reduction in bone disease and improvement in growth through 64 weeks of treatment and sustained effect on bone mineral metabolites in patients under 5 years old

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Biotech Premarket Movers: Insys, Ultragenyx, Alexion

Insys Therapeutics, Ultragenyx Pharmaceutical and Alexion Pharmaceuticals were among the biotech stock movers in premarket trading on Thursday.

Ultragenyx Announces Topline Data From Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study

Overall seizures not significantly reduced; decrease in absence seizures observed